JP Morgan Maintains Neutral on Sage Therapeutics, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $12 to $10.
August 06, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan analyst Anupam Rama maintains a Neutral rating on Sage Therapeutics but lowers the price target from $12 to $10.
The lowered price target from $12 to $10 by JP Morgan suggests a less optimistic outlook for Sage Therapeutics, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100